Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8690390 | 0.98 | SIGMAR1 (0.41) | SIGMAR1BRD4GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL28238994 | 0.98 | SIGMAR1 (0.41) | SIGMAR1BRD4GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL8891238 | 0.90 | SIGMAR1 (0.44) | SIGMAR1BRD4GNAO1GNAI3GNAI1 | |
| SCHEMBL4728642 | 0.86 | SLC6A1 (0.41) | SIGMAR1BRD4HRH3 | |
| SCHEMBL31209878 | 0.86 | SLC6A1 (0.41) | SIGMAR1BRD4HRH3 | |
| SCHEMBL9728089 | 0.86 | SIGMAR1 (0.53) | SIGMAR1BRD4GNAO1GNAI3GNAI1 | |
| SCHEMBL19123031 | 0.86 | SLC6A1 (0.41) | SIGMAR1BRD4HRH3 | |
| Hydrochloric Acid SCHEMBL34474797 | 0.85 | SLC6A1 (0.39) | SIGMAR1BRD4GNAO1HRH3 | |
| Hydrochloric Acid SCHEMBL26107536 | 0.85 | SLC6A1 (0.39) | SIGMAR1BRD4GNAO1HRH3 | |
| Hydrochloric Acid SCHEMBL11715631 | 0.85 | SIGMAR1 (0.52) | SIGMAR1BRD4GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083674-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| CN-113423708-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250064739-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| CN-118900689-A | Oxazolidinone liposome compositions | 阿卡格拉医药公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4452252-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | Akagera Medicines, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-12116361-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | AKAGERA MEDICINES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
| US-20040121997-A1 | 20-hydroxyeicosatetraenoic acid production inhibitors | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1389611-A1 | 20-HYDROXYEICOSATETRAENOIC ACID PRODUCTION INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| EP-0720602-B1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1997-07-09 | — | — | EP | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121997-A1 | 20-hydroxyeicosatetraenoic acid production inhibitors | PTGS1, PTGIS, ALOX5 | SIGMAR1 427/4885BRD4 1272/4885GNAO1 4012/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | SIGMAR1 280/4885BRD4 2047/4885GNAO1 927/4885 |
| US-12116361-B2 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | OXA1L, THPO, TBCD | SIGMAR1 1943/4885BRD4 3345/4885GNAO1 3760/4885 |
| US-20250064739-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | OXA1L, CLPTM1L, AGK | SIGMAR1 3248/4885BRD4 4057/4885GNAO1 3669/4885 |
| US-20260083674-A1 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | TBCD, SLK, PLA2G2C | SIGMAR1 1094/4885BRD4 3778/4885GNAO1 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.